修改后的多纳尼马布定位降低了ARIA风险,并维持了粉样蛋白减少
Hong Wang1, Emel Serap Monkul Nery1, Paul Ardayfio1
1Eli Lilly and Company, Indianapolis, Indiana, USA.
概括
经过修改的多纳尼马布剂量策略显著降低了阿尔茨海默氏病早期患者的ARIA-E风险. 这种方法证明了与标准剂量相比的有效性和安全性,为治疗提供了有前途的替代方案.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- TRAILBLAZER-ALZ 6是一项第3b期研究,研究在早期症状性阿尔茨海默氏症时的多纳纳.
- 该研究评估了替代剂量方案,以优化安全性和有效性.
研究的目的:
- 为了评估与瘤/溢液 (ARIA-E) 相关的粉样蛋白成像异常的相对风险降低,使用替代的donanemab剂量策略.
- 为了比较修改的多纳尼马布定位与标准剂量的安全性和有效性.
主要方法:
- 843名参与者被随机分配到标准和三个替代的donanemab剂量手臂.
- 主要结果是24周的ARIA-E相对风险降低,通过贝叶斯逻辑回归来评估.
- 监测了粉样质斑块水平和donanemab的药理动力学.
主要成果:
- 经过修改的定位臂在24周后显示ARIA-E频率 (13.7%) 与标准臂 (23.7%) 相比显著降低.
- 修改后的标化达到主要终点,与标准剂量相比,达到≥20%的RRR的概率为94%.
- 两只手臂都显示了可比的粉样蛋白减少和药理动力学特征.
结论:
- 逐渐增加多纳尼马布的剂量有效降低阿尔茨海默病患者的ARIA-E风险.
- 修改定位提供了有利的安全性,药理动力学与标准剂量相比较.
- 这些发现支持改性定量作为多纳尼马布治疗中潜在的更安全的剂量策略.
更多相关视频
05:53A Step-By-Step Method to Detect Neutralizing Antibodies Against AAV using a Colorimetric Cell-Based Assay
Published on: December 7, 2021
4.4K
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
405
相关概念视频
01:23EDTA: Indirect and Alkalimetric Titration
2.3K
Unlike direct titration, back-titration, and displacement titration, indirect titration is an EDTA titration method for quantifying anions. In the indirect titration method, anions are precipitated as their insoluble salts with excess metal ions. The filtrate containing the excess metal ions is directly titrated with standard EDTA until the endpoint is achieved. Another approach involves extracting the metal ion and back-titrating with standard EDTA to obtain the endpoint. In this way, the...
2.3K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K